gabapentin has been researched along with Cancer of Head in 17 studies
Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer." | 9.69 | Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023) |
| "The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 9.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
| " At interim analysis, gabapentin use resulted in a decrease in pain (P = ." | 9.34 | Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 9.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 9.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 8.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 7.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 7.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "The addition of venlafaxine to prophylactic gabapentin did not result in improvements in pain control and quality of life among patients with head and neck cancer." | 5.69 | Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial. ( Attwood, K; Farrugia, M; Hermann, G; Iovoli, AJ; Ma, SJ; Neimanis, D; Singh, AK; Smith, KA; Wang, K, 2023) |
| "The purpose of this paper is to determine whether prophylactic gabapentin usage in patients undergoing definitive concurrent chemotherapy and radiation therapy (chemoRT) for oropharyngeal cancer (OPC) improves treatment-related oral mucositis pain, opioid use, and feeding tube (FT) placement." | 5.51 | Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma. ( Ali, H; Chang, S; Cook, A; Fakhoury, L; Ghanem, T; Han, X; Modh, A; Momin, S; Money, S; Movsas, B; Sheqwara, J; Siddiqui, F; Tam, S; Wu, V, 2022) |
| "Prophylactic gabapentin appears to be a promising treatment option for preventing pain, reducing opioids, and reducing weight loss in patients undergoing head and neck cancer therapy." | 5.41 | Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis. ( Murphy, BA; Smith, DK; Smith, LE, 2023) |
| " At interim analysis, gabapentin use resulted in a decrease in pain (P = ." | 5.34 | Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation. ( Cmelak, A; Ghiam, M; Gibson, MK; Gilbert, J; Hawkins, D; Lou, D; Murphy, BA; Niermann, K; Smith, DK, 2020) |
| "HNC patients (pts) receiving CRT were randomized to standard pain control (SPC) with acetaminophen and opioids, or SPC plus gabapentin (SPC+G)." | 5.22 | Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer. ( Chayahara, N; Fujiwara, Y; Funakoshi, Y; Kataoka, T; Kiyota, N; Komori, T; Minami, H; Mukohara, T; Nibu, K; Sasaki, R; Shimada, T; Toyoda, M, 2016) |
| "To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck." | 5.13 | High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers. ( Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C, 2008) |
| "This article reviews the existing literature on the use of gabapentin (Neurontin®) as a co-analgesic in treating the neuropathic pain in OM." | 4.93 | Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck. ( Dutta, PR; Itano, J; Milazzo-Kiedaisch, CA, 2016) |
| "This retrospective study evaluates the efficacy of gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck tumors." | 3.76 | Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy. ( Bar Ad, V; Both, S; Chalian, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "This retrospective study evaluated the efficacy of gabapentin for the treatment of pain syndromes related to radiation-induced mucositis in patients with head and neck cancers treated with concurrent chemoradiation." | 3.76 | Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy. ( Bar Ad, V; Both, S; Chalian, A; Dosoretz, A; Dutta, PR; Quon, H; Weinstein, G, 2010) |
| "Effective postoperative pain management increases patient satisfaction, reduces cost, reduces morbidity, and shortens hospitalizations." | 2.87 | Effect of Perioperative Gabapentin Use on Postsurgical Pain in Patients Undergoing Head and Neck Mucosal Surgery: A Randomized Clinical Trial. ( Bottros, M; Jackson, RS; Kallogjeri, D; Lindburg, M; Liou, T; Nussenbaum, B; Piccirillo, JF; Schoer, M; Scott-Wittenborn, N; Townsend, M, 2018) |
| "Gabapentin (n = 86) was not associated with a reduction in severe pain." | 1.72 | Non-opioid analgesics and post-operative pain following transoral robotic surgery for oropharyngeal cancer. ( Janus, JR; Kasperbauer, JL; Kruthiventi, SC; Moore, EJ; Noel, DB; Olsen, KD; Price, DL; Sauer, AB; Van Abel, KM; Weingarten, TN, 2022) |
| "Gabapentin was independently associated with less opioid use on multivariate analysis at 3 months (OR 0." | 1.72 | Effectiveness of gabapentin in reducing opioid requirements after radiation in head and neck cancer in a single institution. ( Biedermann, GB; Bollig, CA; Clark, AD; Dooley, LM; Gilley, DR; Wieser, ME, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 9 (52.94) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, A | 1 |
| Modh, A | 1 |
| Ali, H | 1 |
| Sheqwara, J | 1 |
| Chang, S | 1 |
| Ghanem, T | 1 |
| Momin, S | 1 |
| Wu, V | 1 |
| Tam, S | 1 |
| Money, S | 1 |
| Han, X | 1 |
| Fakhoury, L | 1 |
| Movsas, B | 1 |
| Siddiqui, F | 1 |
| Van Abel, KM | 1 |
| Sauer, AB | 1 |
| Kruthiventi, SC | 1 |
| Weingarten, TN | 1 |
| Noel, DB | 1 |
| Price, DL | 1 |
| Kasperbauer, JL | 1 |
| Janus, JR | 1 |
| Olsen, KD | 1 |
| Moore, EJ | 1 |
| McDowell, L | 1 |
| Bossi, P | 1 |
| Gilley, DR | 1 |
| Clark, AD | 1 |
| Wieser, ME | 1 |
| Bollig, CA | 1 |
| Dooley, LM | 1 |
| Biedermann, GB | 1 |
| Ma, SJ | 2 |
| Wang, K | 2 |
| Iovoli, AJ | 2 |
| Attwood, K | 2 |
| Hermann, G | 2 |
| Farrugia, M | 2 |
| Singh, AK | 3 |
| Neimanis, D | 1 |
| Smith, KA | 1 |
| Smith, LE | 1 |
| Murphy, BA | 2 |
| Smith, DK | 2 |
| Lee, TS | 1 |
| Wang, LL | 1 |
| Yi, DI | 1 |
| Prasanna, PD | 1 |
| Kandl, C | 1 |
| Cmelak, A | 1 |
| Niermann, K | 1 |
| Ghiam, M | 1 |
| Lou, D | 1 |
| Gilbert, J | 1 |
| Gibson, MK | 1 |
| Hawkins, D | 1 |
| Townsend, M | 1 |
| Liou, T | 1 |
| Kallogjeri, D | 1 |
| Schoer, M | 1 |
| Scott-Wittenborn, N | 1 |
| Lindburg, M | 1 |
| Bottros, M | 1 |
| Jackson, RS | 1 |
| Nussenbaum, B | 1 |
| Piccirillo, JF | 1 |
| Yang, W | 1 |
| McNutt, TR | 1 |
| Dudley, SA | 1 |
| Kumar, R | 1 |
| Starmer, HM | 1 |
| Gourin, CG | 1 |
| Moore, JA | 1 |
| Evans, K | 1 |
| Allen, M | 1 |
| Agrawal, N | 1 |
| Richmon, JD | 1 |
| Chung, CH | 1 |
| Quon, H | 3 |
| Kataoka, T | 1 |
| Kiyota, N | 1 |
| Shimada, T | 1 |
| Funakoshi, Y | 1 |
| Chayahara, N | 1 |
| Toyoda, M | 1 |
| Fujiwara, Y | 1 |
| Nibu, K | 1 |
| Komori, T | 1 |
| Sasaki, R | 1 |
| Mukohara, T | 1 |
| Minami, H | 1 |
| Sanders, JG | 1 |
| Dawes, PJ | 1 |
| Milazzo-Kiedaisch, CA | 1 |
| Itano, J | 1 |
| Dutta, PR | 3 |
| Sharp, H | 1 |
| Morris, JC | 1 |
| Van Waes, C | 1 |
| Gius, D | 1 |
| Cooley-Zgela, T | 1 |
| Bar Ad, V | 2 |
| Weinstein, G | 2 |
| Chalian, A | 2 |
| Both, S | 2 |
| Dosoretz, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma[NCT03269344] | Phase 3 | 65 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients: A Randomized Clinical Trial[NCT02926573] | Phase 4 | 123 participants (Actual) | Interventional | 2016-06-24 | Completed | ||
| A Prospective Randomized Double Blind Trial to Assess the Effect of a Single Preoperative Dose of Gabapentin on Postoperative Opioid Consumption in Patients Undergoing Rhinoplasty[NCT03498261] | Phase 1 | 50 participants (Actual) | Interventional | 2018-01-30 | Active, not recruiting | ||
| Efficacy of Preoperative Administration of Gabapentin in Managing Intraoperative and Postoperative Pain From Third Molar Extractions.[NCT04860141] | Phase 4 | 98 participants (Anticipated) | Interventional | 2021-06-16 | Recruiting | ||
| Effect of Gabapentin on Postoperative Opioid Analgesic Use and Pain in Adolescents Undergoing Tonsillectomy[NCT05024825] | Phase 4 | 17 participants (Actual) | Interventional | 2017-08-04 | Terminated (stopped due to recruitment target not met.) | ||
| A Pilot Phase I Dose Escalation Study Of The EGFR Tyrosine Kinase Inhibitor Gefitinib (Iressa) Combined With Paclitaxel (Taxol) And External Beam Radiation Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And Neck (SCCHN)[NCT00083057] | Phase 1 | 30 participants (Anticipated) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03269344)
Timeframe: Over the entire study period from baseline to follow-up, approximately 13 weeks
| Intervention | Daily morphine equivalents (Median) |
|---|---|
| Control Arm | 15.6 |
| Experimental Arm | 22.2 |
Scale: Patient-reported outcomes of Common Terminology Criteria for Adverse Events (PRO-CTCAE), 5-point Likert scale, higher scores indicate worse outcomes. Range of scores 0-40 (min-max). (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Control Arm | 1.0 |
| Experimental Arm | 6.5 |
Scale tile: Patient Reported Oral Mucositis Symptoms scale, range 0-1000, higher scores indicate worse outcomes (NCT03269344)
Timeframe: Evaluated change in scores from baseline to 6 weeks post-treatment, approximately 13 weeks
| Intervention | score on a scale (Mean) |
|---|---|
| Control Arm | 20.1 |
| Experimental Arm | 29.1 |
Scale: Functional Assessment of Cancer Therapy-Trial Outcome (FACT-HN), range 0-148, higher scores indicate better outcomes (NCT03269344)
Timeframe: Administered at baseline and at 6-week follow-up endpoint, approximately 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| Control Arm | -15.0 |
| Experimental Arm | -20.0 |
Measure of number of patients who required feeding tube placement at any time during the study period (NCT03269344)
Timeframe: Evaluated placement of feeding tube from baseline (start of radiation) to 6 weeks post-treatment, approximately 13 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Control Arm | 6 |
| Experimental Arm | 18 |
Percent weight lost from baseline to week 7 of treatment (end of treatment) (NCT03269344)
Timeframe: Percent change from baseline to week 7 of treatment
| Intervention | Percent change (Median) |
|---|---|
| Control Arm | -10.7 |
| Experimental Arm | -11.4 |
Total amount of narcotic use in morphine equivalents will be divided by the total hours of inpatient hospitalization, multiplied by 24 hours, to obtain the daily narcotic consumption. (NCT02926573)
Timeframe: Daily from date of randomization until post-op day 2 or date of discharge, whichever comes first.
| Intervention | mg/hour (Median) |
|---|---|
| Gabapentin | 1.60 |
| Placebo | 1.59 |
"Subjective pain scores were captured using the Visual Analog Scale (VAS). Subjects were asked to Please rate your current pain level with no movement (rest), with a cough, and with a swallow. Subjects marked a point on a 100-mm line anchored no pain on the left end and worst possible pain on the right end.~Pain literature reports that scores in the 10-30mm range correlate clinically with mild pain, in the 30-60 or 70mm range with moderate pain, and in the >70 range with severe pain" (NCT02926573)
Timeframe: Baseline through post operative day 3
| Intervention | mm (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Post-operative Day 1 7AM | Post-operative Day 1 10AM | Post-operative Day 1 7PM | Post-operative Day 2 7AM | Post-operative Day 2 10AM | Post-operative Day 2 7PM | Post-operative Day 3 7AM | |
| Gabapentin | 36 | 36 | 34 | 34 | 28 | 30 | 27 |
| Placebo | 46 | 45 | 41 | 39 | 39 | 45 | 39 |
"Subjective pain scores were captured using the Visual Analog Scale (VAS). Subjects were asked to Please rate your current pain level with no movement (rest), with a cough, and with a swallow. Subjects marked a point on a 100-mm line anchored no pain on the left end and worst possible pain on the right end.~Pain literature reports that scores in the 10-30mm range correlate clinically with mild pain, in the 30-60 or 70mm range with moderate pain, and in the >70 range with severe pain" (NCT02926573)
Timeframe: Baseline through post operative day 3
| Intervention | mm (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Post-operative Day 1 7AM | Post-operative Day 1 10AM | Post-operative Day 1 7PM | Post-operative Day 2 7AM | Post-operative Day 2 10AM | Post-operative Day 2 7PM | Post-operative Day 3 7AM | |
| Gabapentin | 44 | 29 | 25 | 27 | 23 | 25 | 22 |
| Placebo | 46 | 37 | 32 | 32 | 30 | 33 | 32 |
"Subjective pain scores were captured using the Visual Analog Scale (VAS). Subjects were asked to Please rate your current pain level with no movement (rest), with a cough, and with a swallow. Subjects marked a point on a 100-mm line anchored no pain on the left end and worst possible pain on the right end.~Pain literature reports that scores in the 10-30mm range correlate clinically with mild pain, in the 30-60 or 70mm range with moderate pain, and in the >70 range with severe pain" (NCT02926573)
Timeframe: Baseline through post operative day 3
| Intervention | mm (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Post-operative Day 1 7AM | Post-operative Day 1 10AM | Post-operative Day 1 7PM | Post-operative Day 2 7AM | Post-operative Day 2 10AM | Post-operative Day 2 7PM | Post-operative Day 3 7AM | |
| Gabapentin | 49 | 46 | 41 | 41 | 37 | 40 | 35 |
| Placebo | 48 | 51 | 52 | 48 | 45 | 56 | 52 |
3 reviews available for gabapentin and Cancer of Head
| Article | Year |
|---|---|
Prophylactic gabapentin during head and neck cancer therapy: a systematic review and meta-analysis.
Topics: Amines; Analgesics; Analgesics, Opioid; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric | 2023 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Gabapentin for Perioperative Analgesia in Otorhinolaryngology-Head and Neck Surgery: Systematic Review.
Topics: Amines; Analgesia; Analgesics; Cyclohexanecarboxylic Acids; Evidence-Based Medicine; Gabapentin; gam | 2016 |
Role of Gabapentin in Managing Mucositis Pain in Patients Undergoing Radiation Therapy to the Head and Neck.
Topics: Adult; Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric | 2016 |
6 trials available for gabapentin and Cancer of Head
| Article | Year |
|---|---|
Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Prophylactic Gabapentin for the Reduction of Oral Mucositis Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma.
Topics: Double-Blind Method; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Quality of Life; Squamous Ce | 2022 |
Efficacy of Prophylactic High-Dose Gabapentin and Venlafaxine on Reducing Oral Mucositis Pain Among Patients Treated With Chemoradiation for Head and Neck Cancer: A Single-Institution, Phase 2, Randomized Clinical Trial.
Topics: Analgesics, Opioid; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain; Quality of Life; S | 2023 |
Preventive use of gabapentin to decrease pain and systemic symptoms in patients with head and neck cancer undergoing chemoradiation.
Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Pain; Prospective Studies | 2020 |
Effect of Perioperative Gabapentin Use on Postsurgical Pain in Patients Undergoing Head and Neck Mucosal Surgery: A Randomized Clinical Trial.
Topics: Analgesics; Double-Blind Method; Female; Gabapentin; Head and Neck Neoplasms; Humans; Male; Middle A | 2018 |
Randomized trial of standard pain control with or without gabapentin for pain related to radiation-induced mucositis in head and neck cancer.
Topics: Acetaminophen; Adult; Aged; Amines; Analgesics; Analgesics, Opioid; Antineoplastic Agents; Carcinoma | 2016 |
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ | 2008 |
8 other studies available for gabapentin and Cancer of Head
| Article | Year |
|---|---|
Non-opioid analgesics and post-operative pain following transoral robotic surgery for oropharyngeal cancer.
Topics: Analgesics, Non-Narcotic; Gabapentin; Head and Neck Neoplasms; Humans; Male; Middle Aged; Oropharyng | 2022 |
The Burning Question: Prophylactic Gabapentin for Mucositis-Related Pain in Patients Undergoing Chemoradiation Therapy for Head and Neck Cancer?
Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Mucositis; Pain | 2022 |
Effectiveness of gabapentin in reducing opioid requirements after radiation in head and neck cancer in a single institution.
Topics: Analgesics, Opioid; Gabapentin; Head and Neck Neoplasms; Humans; Opioid-Related Disorders; Retrospec | 2022 |
Association of Gabapentin Use With Pain Control and Feeding Tube Placement Among Patients With Head and Neck Cancer Receiving Chemoradiotherapy.
Topics: Chemoradiotherapy; Gabapentin; Head and Neck Neoplasms; Humans; Intubation, Gastrointestinal; Pain | 2022 |
Opioid sparing multimodal analgesia treats pain after head and neck microvascular reconstruction.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Combined Modality Therapy; Female; Free Tissue Flaps; G | 2020 |
Predictive Factors for Prophylactic Percutaneous Endoscopic Gastrostomy (PEG) Tube Placement and Use in Head and Neck Patients Following Intensity-Modulated Radiation Therapy (IMRT) Treatment: Concordance, Discrepancies, and the Role of Gabapentin.
Topics: Aged; Amines; Analgesics; Cyclohexanecarboxylic Acids; Deglutition Disorders; Enteral Nutrition; Fem | 2016 |
Gabapentin for the treatment of pain related to radiation-induced mucositis in patients with head and neck tumors treated with intensity-modulated radiation therapy.
Topics: Amines; Analgesics; Cyclohexanecarboxylic Acids; Deglutition Disorders; Dose-Response Relationship, | 2010 |
Gabapentin for the treatment of pain syndrome related to radiation-induced mucositis in patients with head and neck cancer treated with concurrent chemoradiotherapy.
Topics: Amines; Analgesics; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamm | 2010 |